Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04844073 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT04844073 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 95 participants.
The verdict
NCT04844073, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101). Participants may receive treatment throughout the study for a maximum of 13 months and will be followed up at 30 days and 90 days and then every 12 weeks for up to 48 weeks after the last treatment.
Interventions
- DRUG TAK-186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2025-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04844073
The ClinicalTrials.gov registry entry for NCT04844073 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-186 is the first listed.
NCT04844073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04844073 about?
NCT04844073 is a clinical study titled "A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer". The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101). Participants may receive treatment throughout the stud...
What is the current status of trial NCT04844073?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2021-03-08. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT04844073?
The interventions under investigation include: TAK-186 (DRUG).
Who is sponsoring clinical trial NCT04844073?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.